Danaher Co. (NYSE:DHR) CFO Matthew Mcgrew sold 7,457 shares of the stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $203.42, for a total value of $1,516,902.94. Following the sale, the chief financial officer now owns 12,387 shares of the company’s stock, valued at $2,519,763.54. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

NYSE:DHR opened at $203.80 on Friday. The stock has a market cap of $142.15 billion, a P/E ratio of 43.64, a price-to-earnings-growth ratio of 3.20 and a beta of 0.92. The firm’s fifty day simple moving average is $182.24 and its 200 day simple moving average is $161.95. Danaher Co. has a twelve month low of $119.60 and a twelve month high of $204.13. The company has a quick ratio of 1.74, a current ratio of 2.20 and a debt-to-equity ratio of 0.68.

Danaher (NYSE:DHR) last announced its earnings results on Thursday, July 23rd. The conglomerate reported $1.44 EPS for the quarter, beating the Zacks’ consensus estimate of $1.09 by $0.35. Danaher had a net margin of 17.73% and a return on equity of 11.88%. The firm had revenue of $5.30 billion for the quarter, compared to analysts’ expectations of $5.01 billion. During the same quarter in the previous year, the business posted $1.09 EPS. The company’s quarterly revenue was up 2.7% on a year-over-year basis. On average, analysts expect that Danaher Co. will post 5.42 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Friday, July 31st. Stockholders of record on Friday, June 26th were issued a dividend of $0.18 per share. This represents a $0.72 dividend on an annualized basis and a dividend yield of 0.35%. The ex-dividend date of this dividend was Thursday, June 25th. Danaher’s dividend payout ratio (DPR) is presently 16.29%.

Several equities research analysts recently weighed in on the company. Credit Suisse Group increased their target price on Danaher from $165.00 to $169.00 and gave the company an “outperform” rating in a report on Thursday, May 21st. Zacks Investment Research upgraded Danaher from a “hold” rating to a “buy” rating and set a $203.00 target price for the company in a report on Tuesday, July 21st. Wolfe Research upgraded Danaher from a “peer perform” rating to an “outperform” rating and set a $195.00 target price for the company in a report on Tuesday, June 16th. UBS Group increased their target price on Danaher from $176.00 to $233.00 and gave the company a “buy” rating in a report on Monday, July 27th. Finally, Robert W. Baird upped their price target on Danaher from $163.00 to $205.00 and gave the company an “outperform” rating in a research report on Friday, July 24th. Two research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $197.73.

Hedge funds have recently made changes to their positions in the company. Howe & Rusling Inc. boosted its holdings in shares of Danaher by 81.4% during the 2nd quarter. Howe & Rusling Inc. now owns 156 shares of the conglomerate’s stock valued at $28,000 after buying an additional 70 shares in the last quarter. Lion Street Advisors LLC bought a new stake in shares of Danaher during the 1st quarter valued at $25,000. Semmax Financial Advisors Inc. bought a new stake in shares of Danaher during the 2nd quarter valued at $35,000. Manchester Financial Inc. boosted its holdings in shares of Danaher by 50.0% during the 1st quarter. Manchester Financial Inc. now owns 228 shares of the conglomerate’s stock valued at $32,000 after buying an additional 76 shares in the last quarter. Finally, Trustcore Financial Services LLC boosted its holdings in shares of Danaher by 36.9% during the 2nd quarter. Trustcore Financial Services LLC now owns 230 shares of the conglomerate’s stock valued at $41,000 after buying an additional 62 shares in the last quarter. Hedge funds and other institutional investors own 77.67% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments; Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables.

Read More: What is the definition of arbitrage?

Insider Buying and Selling by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.